secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
CIK:        0001757499
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0001493152-25-010211
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 3.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shuttle Pharma raises $5.75M in public offering, regains Nasdaq equity compliance
--------------------------------------------------------------------------------

- Closed underwritten offering of 1.34M shares and 17.8M pre-funded warrants at $0.30/share, net proceeds ~$5.2M.
- Net proceeds to fund Phase II trial of Ropidoxuridine, $2.8M to CRO Theradex, plus up to $2.0M for marketing.
- Believes it has regained compliance with Nasdaq minimum stockholders' equity rule of $2.5M after offering.
- Offering was sole-underwritten by WestPark Capital; closed March 13, 2025.
- Previously received Nasdaq deficiency notice on Sep 10, 2024; plan accepted Nov 26, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1757499/000149315225010211/0001493152-25-010211-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1757499/000149315225010211/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-010211

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer